Another novel approach is being pursued by Wisconsin-based ConjuGon (http://www.conjugon.com/). This eight-person startup is using bacterial sexual reproduction to spread lethal genes in pathogen communities. When the lethal genes are expressed, the bacterial population dies out.“I'm a plasmid biologist,” says Marcin Filutowicz, professor of bacteriology at the University of Wisconsin-Madison, and one of ConjuGon's founders. “Bacterial plasmids are extra chromosomal elements that bacteria don't need to live. They transfer DNA molecules among bacteria. They carry genes which frequently encode for antibiotic resistance. Most of the DNA that is transferred between bacteria is done through plasmid exchange.” ConjuGon engineers specific plasmids with DNA that encodes toxins as well as benign bacteria that are immune to the toxins encoded by the plasmids. When immune bacteria transfer the plasmid that encodes for the toxins to the recipient bacteria, such as a pathogen like Pseudomonas aeruginosa, during conjugation the toxin is expressed, killing the pathogen.“It is a Trojan-horse-like approach where we introduce a DNA molecule from donor to recipient and then express in the recipients multiple toxins or single toxins,” says Filutowicz. “When we express multiple toxins, we reduce the probability for the recipient bacteria to acquire immunity.”ConjuGon is targeting genes that encode for antibiotics that block a certain RNA polymerase at several different locations in bacteria. The company has a patent on “Sigma Binding of RNA Polymerase and Uses Therof” for its method of high-throughput screening for small-molecule drugs that interfere with the binding of transcription factor sigma to the core RNA polymerase. ConjuGon chose this target because it is unlikely that bacteria would mutate in enough multiple ways to evade a compound that interferes with this interaction.Conjugon recently received a phase I SBIR grant from the Army to do research on a treatment for antibiotic-resistant Acineobacter baumannii infections contracted by wounded soldiers in Iraq and Afghanistan. Additionally, Ravi Shankar, associate professor, Department of Surgery and Cell Biology, Neurobiology & Anatomy Burn and Shock Trauma Unit at Loyola University Medical Center, is conducting the proof-of-concept studies on ConjuGon's approach on mice. Shankar is interested in ConjuGon's approach as a specialized or adjunct therapy for patients with burn or trauma wounds who have a long healing process. “Much of the time, especially with burn-wound cases, it is not about life or death. It is about achieving adequate wound coverage with grafts or synthetic material so the person can heal faster,” Shankar says. “But unfortunately, if you have an infection, many of the grafts fail. They lift off.” Conventional antibiotic therapy can be problematic as the antibiotic has to be delivered to the actual wound area of the patient. Thus, a systemic antibiotic is not enough. A majority of time, wound care is delivered via topical antibiotics and antimicrobials, such as topical silver emulsions.Shankar says that in the mouse studies that pathogens were totally eliminated within 30 min of administering ConjuGon treatment. “It actually works…. We have to see if it works on human beings,” Shankar says.
Read full abstract